Anocca

Anocca is a privately held Swedish biotechnology company founded in 2014 with the mission to build a unique T-cell biology analytics technology platform to unlock the therapeutic potential of T-cell immunity. Anocca’s technology enables highly precise and effective analysis of T-cell biology to deliver a range of therapeutic approaches specifically harnessing or modulating T-cell immunity across many disease areas. Focused on delivering TCR-modified T-cell therapies (TCR-T) in oncology, Anocca is leveraging its own manufacturing capabilities to rapidly advance a series of novel T-cell therapies into clinical trials. Anocca’s robust technology is also being utilized to develop a range of novel therapeutic and preventative products in the fields of oncology, infectious diseases, and autoimmunity.